ROS1 G2032R: The Solvent-Front Mutation and Repotrectinib

ROS1 fusions drive 1–2% of non-small cell lung cancers, and crizotinib became the first approved TKI for this patient population. But acquired resistance emerges, and the G2032R substitution—located at the ATP-binding pocket's solvent-exposed front—is one of the most frequent on-target mechanisms. Understanding why this single amino-acid swap abolishes crizotinib binding, and how next-generation agents like repotrectinib overcome it, illustrates the interplay between kinase conformational dynamics and inhibitor geometry.

ROS1 and First-Generation Inhibitors

ROS1 is a receptor tyrosine kinase with high sequence homology to ALK in the ATP-binding pocket. Crizotinib, originally an ALK/MET inhibitor, shows potent activity against ROS1 fusions and was approved for ROS1-positive NSCLC in 2016. The drug occupies the ATP site in the DFG-in inactive conformation, forming a hydrogen bond to the hinge and exploiting a hydrophobic back pocket created by the gatekeeper residue.

Clinical responses are often durable, but relapse occurs. Resistance mutations cluster in the kinase domain, with G2032R emerging as a recurrent substitution analogous to ALK G1202R and EGFR T790M in their respective structural contexts. The glycine-to-arginine change introduces a bulky, positively charged side chain at the solvent front, sterically and electrostatically clashing with the 2,6-dichloro-3-fluorophenyl moiety of crizotinib.

The Solvent-Front Position and G2032R

Glycine 2032 sits at the lip of the ATP-binding cleft, adjacent to the P-loop and the hinge region, defining the boundary between the buried active site and bulk solvent. In the wild-type structure, the absence of a side chain at this position leaves an open channel, permitting ligands with extended aromatic or halogenated substituents to occupy space without steric penalty.

Mutation to arginine—bearing a long aliphatic chain terminating in a guanidinium group—reshapes this region. The arginine side chain can adopt multiple rotamers, but in the G2032R mutant structures, it typically projects into the pocket, occluding the volume occupied by crizotinib's dichlorofluorophenyl ring. Electrostatic repulsion between the positively charged guanidinium and any electron-withdrawing groups on the inhibitor further destabilizes binding.

This solvent-front mechanism differs from gatekeeper mutations like T790M in EGFR, where a bulkier residue narrows the back pocket. Instead, G2032R reshapes the entrance, creating a new steric barrier. First-generation inhibitors, designed for the wild-type pocket geometry, lose affinity by one to two orders of magnitude against G2032R.

Repotrectinib: A Macrocyclic Solution

Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor featuring a macrocyclic core. The 15-membered macrocycle enforces a constrained conformation that presents the key pharmacophore elements—hinge binder, hydrophobic groups—in a compact, pre-organized geometry. This rigidity reduces the entropic penalty of binding and allows the molecule to navigate the altered topology of the mutant pocket.

Critically, repotrectinib's design avoids direct clash with the Arg2032 side chain. The macrocycle directs substituents away from the solvent front, instead filling the back pocket and hinge region where the mutant structure remains permissive. The compound maintains low-nanomolar potency against ROS1 G2032R in biochemical and cellular assays, and clinical data confirm responses in patients with this resistance mutation.

The macrocycle also enhances selectivity. By restricting conformational flexibility, repotrectinib reduces off-target kinase binding, a favorable trait given the need for sustained dosing in relapsed settings.

Docking Wild-Type vs. G2032R: Practical Considerations

Comparing wild-type ROS1 and the G2032R mutant by docking reveals the structural basis for differential inhibitor sensitivity. When docking crizotinib into wild-type ROS1, the ligand adopts the expected pose: hinge H-bond via the aminopyridine, the dichlorofluorophenyl group extending toward the glycine at position 2032, and hydrophobic contacts with the gatekeeper and DFG motif.

In the G2032R mutant, the same docking protocol produces poses with elevated strain. The arginine side chain, even in its most favorable rotamer, encroaches on the halogenated ring, leading to steric clashes flagged by most scoring functions. Energy minimization may displace the ligand or rotate the arginine, but the net result is a higher predicted binding free energy and lower docking score.

Repotrectinib, by contrast, docks successfully into both wild-type and G2032R structures. The macrocycle occupies the adenine pocket, the hinge binder engages Met2029, and the compact scaffold avoids the solvent-front clash zone. Scoring functions report comparable or even improved scores in the mutant, consistent with the maintained biochemical potency.

These docking experiments underscore the value of mutation-aware virtual screening. Evaluating a compound against both wild-type and clinically relevant resistance mutants early in the design cycle can prioritize scaffolds with broad coverage and anticipate resistance liabilities.

Setting Up the Comparison in Liganx

To explore ROS1 wild-type and G2032R side by side, retrieve a representative ROS1 kinase domain structure and prepare the mutant model. The wild-type can be sourced from available crystal structures, while the G2032R mutant may require homology modeling or a published structure if available. In Liganx Studio, load both receptor files, define the binding site around the ATP pocket, and dock your panel of ROS1 inhibitors—crizotinib, entrectinib, repotrectinib—against each target.

Compare the top-ranked poses: does crizotinib show clashes with Arg2032? Does repotrectinib maintain its binding mode? For a detailed workflow on handling point mutations and interpreting pose quality, see our mutation docking guide. Overlay the wild-type and mutant poses to visualize how the arginine side chain reshapes ligand-accessible volume and which chemical features remain tolerated.

Implications for Structure-Based Design

The ROS1 G2032R case illustrates a broader principle: resistance mutations redefine the pharmacophore requirements. Solvent-front mutations like G2032R create new steric gates that first-generation inhibitors, optimized for wild-type pockets, cannot traverse. Successful next-generation agents either avoid the clash zone through conformational constraint (macrocycles) or employ alternative binding modes (non-ATP-competitive allosteric inhibitors, though none are yet approved for ROS1).

For medicinal chemists, this emphasizes the importance of anticipatory design. Building a compound library tested against a panel of known resistance mutations—G2032R, D2033N, L2026M—can identify scaffolds robust to mutational escape. Docking and free-energy perturbation calculations, when calibrated against experimental data, provide a quantitative basis for prioritization.

Repotrectinib's macrocyclic architecture is one solution, but other strategies are emerging: covalent warheads targeting cysteines engineered near the active site, bivalent inhibitors bridging the ATP pocket and an allosteric site, or PROTACs that degrade the mutant kinase irrespective of active-site geometry. Each approach has trade-offs in synthesis, pharmacokinetics, and selectivity.

Conclusion

ROS1 G2032R exemplifies how a single residue substitution at the solvent front can confer high-level resistance to first-generation TKIs. The mutation reshapes the entrance to the ATP-binding pocket, introducing steric and electrostatic barriers that disrupt crizotinib binding. Repotrectinib overcomes this through a macrocyclic scaffold that avoids the clash zone and maintains affinity across wild-type and mutant contexts.

Comparative docking of wild-type and G2032R structures provides immediate insight into these mechanisms, guiding the design of resistance-aware kinase inhibitors. As clinical sequencing identifies resistance mutations earlier and more routinely, integrating mutant-structure modeling into the drug-discovery workflow becomes not just useful but essential.

References

• Awad, M. M., et al. (2021). Acquired resistance to crizotinib from a mutation in CD74–ROS1. N. Engl. J. Med. 368, 2395–2401. DOI: 10.1056/NEJMoa1215530
• Drilon, A., et al. (2018). A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. J. Clin. Oncol. 36, 102. DOI: 10.1200/JCO.2018.36.15_suppl.102
• Katayama, R., et al. (2015). The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat. Commun. 10, 3604. DOI: 10.1038/s41467-019-11496-z
• Drilon, A., et al. (2022). Repotrectinib in ROS1 fusion–positive non–small-cell lung cancer. N. Engl. J. Med. 390, 118–131. DOI: 10.1056/NEJMoa2302299